



Crescendo Biologics to present at BIO International and ICCS in San Diego, US

Cambridge, UK, 2 June 2017 – Crescendo Biologics Limited (Crescendo), the developer of multi-functional Humabody® therapeutics, today announces it will be presenting at the BIO International Convention 2017, San Diego, US, 19-22 June 2017 and satellite event 6th International Cancer Cluster Showcase (ICCS) 2017.

Brian McGuinness, Head of New Product and Business Opportunities, will be presenting as part of the OBN delegation at ICCS, focusing on the Company's development of novel multifunctional Humabody® therapeutics.

Date: Monday 19 June 2017

Time: 13:30

Presentation length: 5 minutes

Location: Upper level 26 AB + 27 AB, San Diego Convention Center, 111 West Harbor Drive, San Diego, California, US, CA 92101

CEO, Peter Pack, will give a company presentation at the BIO International Convention where he will be speaking about Crescendo's Humabody® platform and the company's robust development pipeline of multifunctional IO modulators and Humabody® Drug Conjugates. Humabody® therapeutics demonstrate new modes of action, superior biodistribution and better therapeutic index.

Date: Tuesday 20 June 2017

Time: 11:30

Presentation length: 13 minutes

Location: Company Presentation Theater 4, San Diego Convention Center, 111 West Harbor Drive, San Diego, California, US, CA 92101

For more information on Crescendo's presentations or for media enquiries, please contact crescendo@instinctif.com.

Ends

For more information, please contact:

Crescendo Biologics Dr Peter Pack, CEO	Tel:44 (0)1223 497140 info@crescendobiologics.com
Instinctif Partners Dr Christelle Kerouedan / Melanie Toyne-Sewell	Tel:44 (0)20 7457 2020 crescendo@instinctif.com



Notes to Editors:

About Crescendo Biologics Ltd

Crescendo Biologics is a biopharmaceutical company developing potent, highly differentiated multi-functional Humabody[®] therapeutics in oncology. It is pursuing novel Humabody[®]-based product opportunities, through in-house development and strategic partnerships in both multi-functional immuno-oncology modulators and Humabody[®] Drug Conjugates (HDCs), the next generation of ADCs. The Company's Humabody[®] therapeutics are based on its unique, patent protected, transgenic mouse platform generating 100% human V_H domain building blocks (Humabody[®] V_H) comprising the full structural diversity of the human V_H repertoire and superior biophysical properties as result of their in vivo maturation .

Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Touchstone Innovations (formerly known as Imperial Innovations), Takeda and Astellas.

For more information, please visit the website: www.crescendobiologics.com

About Humabody[®] Therapeutics

Humabodies are a novel class of extremely small, robust and potent protein therapeutics. They are based on fully human V_H domain building blocks (Humabody[®] V_H) isolated from heavy chain-only antibodies produced using Crescendo's proprietary transgenic mouse.

Compared with monoclonal antibodies, Humabodies[®] offer a unique combination of potential benefits resulting from their broad structural diversity, small size, high yield and robust biophysical properties. These attributes allow Crescendo to configure an almost limitless range of multi-specific and multi-functional Humabody[®] formats in a rapid timeframe.

Crescendo is developing a pipeline of novel, Humabody[®]-based therapeutics in oncology. Next-generation multi-specific Humabody[®] IO modulators are optimally configured for targeting a range of key mechanisms in the cancer immunity cycle. These include blocking inhibitory signals or activating stimulatory pathways of the immune response as well as specific targeting of IO modulators into the tumor-microenvironment, enhancing antigen presentation and inhibiting the immunosuppressive tumor microenvironment. Humabody[®] Drug Conjugates (HDCs) demonstrate a superior therapeutic index to standard ADCs

For more information, please visit the website: www.crescendobiologics.com/humabody



About BIO International Convention

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

BIO performs many services for members, but none of them are more visible than the BIO International Convention. The BIO International Convention helps BIO fulfill its mission to help grow the global biotech industry. Profits from the BIO International Convention are returned to the biotechnology industry by supporting BIO programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.

The key benefits of attending the BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry thought-leaders with over 1,500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 76 countries.

For more information, please visit the website: www.convention.bio.org/.

About International Cancer Cluster Showcase

For each of the last 5 years, 200+ representatives of the international oncology community joined ICCS, participating in this focused and dynamic meeting. Come enjoy a kick-start into BIO 2017 partnering activities.

Cutting edge oncology innovations from leading North American and European industry clusters will be presented in compact 4 min presentations giving you the opportunity to learn about the latest innovations from about 20+ companies.

For more information, please visit the website: www.internationalcancercluster.org/.